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Abstract: Peptide-based vaccines for cancer have many advantages however, for optimization these
immunogens should incorporate peptide epitopes that induce CD8, as well as CD4 responses,
antibody and long term immunity. Cell penetrating peptides (CPP) with a capacity of cytosolic
delivery have been used to deliver antigenic peptides and proteins to antigen presenting cells
to induce cytotoxic T cell, helper T cell and humoral responses in mice. For this study,
a tripartite CPP including a mucin 1 (MUC1) variable number of tandem repeat (VNTR) containing
multiple T cell epitopes and tetanus toxoid universal T helper epitope peptide (tetCD4) was
synthesised (AntpMAPMUC1tet) and immune responses investigated in mice. Mice vaccinated
with AntpMAPMUC1tet + CpG show enhanced antigen-specific interferon-gamma (IFN-γ) and IL-4
T cell responses compared with AntpMAPMUC1tet vaccination alone and induced a Th1 response,
characterised by a higher ratio of IgG2a antibody/IgG1 antibodies. Furthermore, vaccination
generated long term MUC1-specific antibody and T cell responses and delayed growth of MUC1+ve
tumours in mice. This data demonstrates the efficient delivery of branched multiple antigen peptides
incorporating CPP and that the addition of CpG augments immune responses.
Keywords: penetratin; membrane translocating peptide; membrane penetrating peptide; vaccine;
Mucin 1; immunogenicity; antigen delivery; immunotherapy; multiple antigen peptide; TLR agonist
1. Introduction
Despite encouraging results in some clinical trials, cancer vaccines are yet to have an impact on
cancer [1,2]. Many strategies specific for a particular tumour associated antigen (TAA), including single
or multiple peptides with or without ex vivo dendritic cells (DC) pulsing, DC targeting immunogens
with or without adjuvants such as a toll-like receptor (TLR) agonist have been used [2–6]. To overcome
some of the limitations of previous peptide vaccine strategies it is necessary to (1) incorporate both
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CD8 cytotoxic T cell (Tc) and CD4 T helper cell (Th) epitopes to promote the generation of long term
immunity; (2) MHC restriction must be considered to allow application to the wider population and;
(3) consideration to the most effective adjuvant to enhance immunogenicity [7–10].
Many TAA have been used as targets for cancer vaccines including Mucin 1 (MUC1), MAGE,
NY-ESO-1, Her-2/neu and others [11,12]. MUC1, is a type I transmembrane glycoprotein with
a protein core consisting of a 20 amino acid variable number of tandem repeat (VNTR) region
(PGSTAPPAHGVTSAPDTRPA), which is frequently over-expressed by adenocarcinoma cells at levels
10–100 times greater than on normal tissues [13,14]. In a 2009 National Cancer Institute pilot project
prioritizing 75 cancer antigens, MUC1 was ranked second as an immunotherapeutic cancer vaccine
target antigen [15]. The 20 amino acid repeat of MUC1 contains T cell epitopes, that can be presented
by many mouse H-2 haplotypes, including H-2Kb, human HLA-A2.1, A1, A3, A11, a Th peptide that
can be presented by HLA-DR3 and B cell epitopes. MUC1 peptide and protein based vaccines have
been investigated in many clinical trials in numerous formulations [14,16–18].
Cell penetrating (CPP) or membrane translocating peptides (MTP) are a group of cationic peptides
that have the ability to enter the cytoplasm of cells [19]. These peptides have been used to deliver a
number of cargos such as proteins, peptides, DNA, RNA, drugs and virus particles into cells [19–22].
For these purposes 2 CPP, TAT from the human immunodeficiency virus transactivator of transcription
protein and penetratin from the Drosophila Antennapedia domain have been used extensively. The
Drosophila Antennapedia DNA binding domain contains 60 amino acids and consists of 3 α-helices, and
the 16 amino acid peptide penetratin (RQIKIWFQNRRMKWKK; Antp) with internalizing activity is
within the third helix.
The cell penetrating property of these peptides have been utilized to deliver antigenic peptide
and proteins into any antigen presenting cell including DCs for the development of vaccine delivery
systems [4,23–39]. For this purpose, CPP peptides chemically conjugated to protein antigens or linear
synthetic peptides of CPP fused in tandem with cytotoxic (Tc) or helper (Th) T cell epitopes have
been used. Mice immunised with these constructs generated antigen-specific CD4, CD8 or mixed
responses and were protected from a subsequent tumor challenge [4,30,40]. To increase the versatility
of penetratin-based immunogens, it has been chemically linked a 4-arm multiple antigen peptide
(MAP) with 4 ovalbumin (OVA) H2-Kb Tc epitope peptides (SIINFEKL) to the CPP, which resulted
OVA-specific immunity and protection from tumour challenge in mice [24]. In the current study, the
immunogenicity of a novel tripartite peptide incorporating penetratin, tetanus toxoid universal CD4
epitope peptide and a single VNTR of the MUC1 antigen is investigated.
Toll-like receptors (TLR) are a family of conserved pattern recognition receptors that recognizes
specific microbial patterns. To enhance immunogenicity, simultaneous delivery of an adjuvant along
with tumour antigens represents an effective approach to vaccination [41]. Unmethylated CpG DNA is
recognized by TLR9, poly(I:C) recognised by TLR3, imidazoquinolines imiquimod and resiquimod
recognizing TLR7/8, TLR4 and TLR2 have been used extensively. A few studies have investigated the
potential of CPP-based immunogens to enhance immunogenicity [24,37,42].
In the current study, we demonstrate that a tripartite branched CPP incorporating the H-2Kb
(SAPDTRPAP)- and HLA-A2 (STAPPAHGV)-restricted CTL epitopes from the MUC1 tumour antigen
with the universal Th epitope tetanus toxoid (tetCD4) is internalised into DC in vitro, as well as in vivo.
The tripartite peptide when combined with CpG induced T cell responses as measured by IFNγ and
IL4 ELISpot analysis, in vivo CTL and protected mice from a tumour challenge. Additionally, long
term MUC1-specific antibody and T cell responses were generated by the tripartite peptide.
2. Results
2.1. Biochemical and Immunochemical Characterisation of the Tripartite Peptide Containing Penetratin, MUC1
VNTR and Tetanus Toxin CD4 Peptide
The tripartite peptide consisting of penetratin (RQIKIWFQNRRMKWKKENK), tetanus
toxoid universal T cell epitope (QYIKANSKFIGITEL) and a single VNTR from MUC1
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(PGSTAPPAHGVTSAPDTRPAPGS) (Figure 1A) was synthesised by solid phase peptide synthesis and
had a purity of >85% and expected mass of 6846.77 by mass spectroscopy.
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arent molecular weight of ~10 kDa (Figure 1B). This discrepancy is probably due to the absence of a
tertiary structure and not migratin at a desired molecular weight position determined by the globular
pr tein molecular weight standards. Western blot analysis of the SDS-PAGE gel with the antibody
1.3.14 reactive with the APPAH sequence identified the band at ~10 kDa (Figure 1B). The antibodies
1.3.14 and BC2 with specificity to APPAH and DTR also bound the tripartite peptide in an ELISA
confirming presence of MUC1Kb (SAPDTRPAP) and MUC1A2 (STAPPAHGV) peptide epitopes in
AntpMAPMUC1tet (Figure 1C). The presence of the tetanus toxoid epitope was determined using
a tetanus peptide-specific CD4 T cell line generated by in vitro priming of PBMC with the tetCD4
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peptide. These bulk cultures contained ~40% tetCD4-specific T cells when stimulated with 20 µM
tetCD4 (not shown). Autologous MoDCs pulsed with AntpMUC1tet stimulated the tetCD4-specific
T cell line as detected by intracellular IFNγ secretion (Figure 1D) by flow cytometry. The levels of
intracellular IFNγ secreted were not significantly different to that induced when tetCD4 peptide alone
or when an AntptetCD4 fusion peptide was used for stimulation. No significant IFNγ was induced in
tetCD4-specific T cells when stimulated by the Antp peptide, unpulsed cells or an irrelevant antigen,
ovalbumin (OVA). These biochemical and immunochemical assays further confirmed the identity of
the tripartite peptide for further immunological studies.
2.2. Internalisation of AntpMAPMUC1tet by Bone Marrow Derived Dendritic Cells (BMDC)
The mechanism of cellular uptake of CPP has been an area of great interest. Cell fixation leads
to the artefactual uptake of these peptides. The DTR sequence within the H2-Kb restricted peptide
epitope is recognised by the BC2 antibody enabling detection of internalised AntpMAPMUC1tet
peptide without chemical modification [23]. Thus, to assess the uptake of AntpMUC1tet by DC, surface
and intracellularly localised peptide was measured by flow cytometry staining with the BC2 antibody.
To investigate the internalisation of AntpMAPMUC1tet, DC were pulsed with varying concentrations
of AntpMAPMUC1tet for 60 min (Figure 2A).
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Figure 2. Uptake of AntpMAPMUC1tet peptide by dendritic cells (DC) in vitro. (A) DC were pulsed with
AntpMAPMUC1tet peptide at either varying concentrations (5 to 200 µg/mL) for 60 min or (B) a constant
dose of 100 µg/mL for set times between 5 and 60 min. Uptake was determined by flow cytometry as the
percent surface staining subtracted from the percent intracellular staining (mean ± SEM, for 3 replicates).
(C) DCs were incubated with 100 µg/mL Alexa-labelled AntpMAPMUC1tet (green) in chamber slides
for 2 h, counterstained with Hoechst nuclear stain (blue), washed and visualized by confocal microscopy
or (D) DC were pre-treated with 10 µg/mL cytochalasin D before AntpMAPMUC1tet pulsing.
Moderate uptake of AntpMAPMUC1tet is seen at 20 µg/mL, with maximum uptake at 100 µg/mL
and plateau at 200 µg/mL. To investigate kinetics of uptake DC were incubated at various times with
AntpMAPMUC1tet (5–60 min) at a fixed concentration (100 µg/mL) and internalisation determined.
Rapid uptake was observed within 5 min, remaining constant for 60 min (Figure 2B).
To further investigate he intracellular uptake by BMDC, Alexa-488-labelled AntpMAPMUC1tet
was used for confocal microscopy [43]. AntpMAPMUC1tet containing vesicles were detectable after 2 h
incubation with BMDC (Figure 2C,D). Addition of cytochalasin D which disrupts actin microfilaments
substantially inhibited uptake leading to diffuse fluorescence indicating the role of macropinocytosis
or phagocytosis in AntpMAPMUC1tet peptide internalisation by BMDC (Figure 2D). Therefore,
Molecules 2018, 23, 2233 5 of 21
the branched CPP containing immunogen is rapidly internalised into DC similar to the linear CPP or
covalently linked immunogens [23,43,44].
2.3. AntpMAPMUC1tet Targets Antigen Presenting Cells (APC) In Vivo
To examine the in vivo localisation of AntpMAPMUC1tet, lymph node cells isolated from mice
18 h after FITC-conjugated AntpMAPMUC1tet injection were analysed for FITC fluorescence intensity
by flow cytometry [45]. As shown in Figure 3A F4/80hi macrophages, CD3+ T cells, and CD19+
B cells show some FITC-AntpMAPMUC1tet binding. However, CD11chi DC show considerably
higher uptake suggesting that AntpMAPMUC1tet preferentially targets professional APC after i.d.
immunisation. Based on CD8 and DEC205 expression, CD11chi DCs can be further divided into
three subpopulations: CD8− DEC205− (immature), CD8+ DEC205− (immature) and CD8low DEC205+
DCs (mature) [46]. To further investigate the uptake by DC, all three subsets were analysed by flow
cytometry indicating that AntpMAUC1tet target the mature CD8low DEC205+ DCs subset (Figure 3B).
Thus, AntpMAPMUC1 is internalised into DC in vitro (above), as well as in vivo.
Molecules 2018, 23, x 5 of 21 
microfilaments substantially inhibited uptake leading to diffuse fluorescence indicating the role of 
macropinocytosis or phagocytosis in AntpMAPMUC1tet peptide internalisation by BMDC (Figure 
2D). Therefore, the branched CPP containing immunogen is rapidly internalised into DC similar to 
the linear CPP or covalently linked immunogens [23,43,44]. 
2.3. AntpMAPMUC1tet Targets Antigen Presenting Cells (APC) In Vivo 
To examine the in vivo localisation of AntpMAPMUC1tet, lymph node cells isolated from mice 
18 h after FITC-conjugated AntpMAPMUC1tet injection were analysed for FITC fluorescence 
intensity by flow cytometry [45]. As shown in Figure 3A F4/80hi macrophages, CD3+ T cells, and CD19+ 
B cells show some FITC-AntpMAPMUC1tet binding. However, CD11chi DC show considerably 
higher uptake suggesting that AntpMAPMUC1tet preferentially targets professional APC after i.d. 
immunisation. Based on CD8 and DEC205 expression, CD11chi DCs can be further divided into three 
subpopulations: CD8− DEC205− (immature), CD8+ DEC205− (immature) and CD8low DEC205+ DCs 
(mature) [46]. To further investigate the uptake by DC, all three subsets were analysed by flow 
cytometry indicating that AntpMAUC1tet target the mature 8low EC205+ DCs subset (Figure 3B). 
Thus, AntpMAPMUC1 is internalised into DC in vitro (ab ),  ll  i  vivo. 
 
Figure 3. AntpMAPMUC1tet targets APC in vivo. Popliteal lymph nodes were isolated from mice (n 
= 4) 18 h after i.d. immunisation with PBS or FITC-labelled AntpMAPMUC1tet. (A) Lymph node cells 
were stained with anti-CD3, CD19, CD11c and F4/80 antibodies. (B) Cells were labelled with CD11c, 
CD8 and DEC205 to separate DC subsets and analysed by flow cytometry. Each labelled population 
was analysed for FITC fluorescence intensity. Results are depicted as histograms representative of 
two separate experiments. 
2.4. Addition of CpG to AntpMAPMUC1tet Induces Maturation of DCs In Vivo 
The activation of TLR on DCs by their corresponding ligands results in the induction of a mature 
phenotype of DCs, inducing the up regulation of MHC and co-stimulatory (CD80 and CD86) 
molecules, thus potentially augmenting T cell stimulatory capacity [47,48]. To assess the maturation 
of DC in vivo C57BL/6 mice were injected i.d. with AntpMUC1tet with or without CpG on the 
footpads and 18 h later popliteal lymph nodes were removed, and cells stained with the DC marker 
CD11c and maturation markers (CD40, CD80, CD86, and MHC class II) assessed by flow cytometry. 
Analysis indicated that i.d. injection of AntpMAPMUC1tet alone does not mature DC in vivo, only 
AntpMAPMUC1tet + CpG immunisation matures DCs in vivo, characterised by increased expression 
of CD40, CD80, CD86, and MHC class II (Figure 4). 
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were stained with anti-CD3, CD19, CD1 c and F4/ ti ies. (B) Cells were labelled with CD11c,
CD8 and DEC205 to separ te DC subsets and analys fl t etry. Each labelled population
was analysed for FITC fluoresc nce inte sity. Results are d picted as histograms representative of two
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2.4. Addition of CpG to AntpMAPMUC1tet Induces Maturation of DCs In Vivo
The activation of TLR on DCs by their corresponding ligands results in the induction of a mature
phenotype of DCs, inducing the up regulation of MHC and co-stimulatory (CD80 and CD86) molecules,
thus potentially augmenting T cell stimulatory capacity [47,48]. To assess the maturation of DC in vivo
C57BL/6 mice were injected i.d. with AntpMUC1tet with or without CpG on the footpads and 18 h later
popliteal lymph nodes were removed, and cells stained with the DC marker CD11c and maturation
markers (CD40, CD80, CD86, and MHC class II) assessed by flow cytometry. Analysis indicated that
i.d. injection of AntpMAPMUC1tet alone does not mature DC in vivo, only AntpMAPMUC1tet + CpG
immunisation matures DCs in vivo, characterised by increased expression of CD40, CD80, CD86, and
MHC class II (Figure 4).
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Figure 5. In vivo IF -γ and IL4 response to ntp P C1tet and ntp P C1tet + CpG in
C57BL/6. C57BL/6 mice were injected i.d. on day 0, 10 and 17 with PBS, 100 µg AntpMAPMUC1tet and
AntpMAP UC1tet + CpG. Number of IFN-γ secreting cells (A) and IL4-secreting cells (B) to MUC1Kb
(SAPDTRPAP) and tetCD4 antigens were analysed by ELISpot assay. ConA (1 µg/mL) was used as an
internal positive control (not shown). Results are shown as mean spot-forming units (SFU)/5 × 105 cells
± SEM. Results are representative of three separate experiments. * p < 0.05, ** p < 0.001.
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Analysis of IL-4 secretion by splenocytes revealed that both AntpMAPMUC1tet and
AntpMAPMUC1tet + CpG immunisation generates significantly higher responses against tetanus
toxoid T helper peptide (tetCD4) when compared to PBS control group (p < 0.05). Similarly, mice
immunised with AntpMAPMUC1tet generated significantly higher responses (p < 0.05) against
SAPDTRPAP (MUC1Kb) compared to PBS group (Figure 5B). However, the IL4 response in the
CpG groups were not significantly different to AntpMUC1tet alone.
2.6. AntpMAPMUC1tet Immunisation Induces Specific T Cell Responses In Vivo in HLA-A2 Transgenic Mice
To establish if immunisation with AntpMAPMUC1tet could generate MUC1 HLA-A2.1-restricted
STAPPAHGV-specific responses human MHC I, HLA-A2*0201/Kb mice were used. HLA-A2 transgenic
mice were immunised i.d. with PBS, 100 µg AntpMAPMUC1tet or AntpMAPMUC1tet + CpG on
days 0, 10 and 17 and IFN-γ and IL-4 responses measured 14 days after final immunisation. Pulsing
splenocytes with the HLA-A2 STAPPAHGV peptide induced significant IFN-γ responses in both
AntpMAPMUC1tet and AntpMAPMUC1tet + CpG groups (p < 0.001). Low but significant IFN-γ
responses were also seen in groups against tetanus toxoid (Figure 6A). Analysis of IL-4 secretion by
splenocytes from mice revealed only mice immunised with AntpMAPMUC1tet + CpG generated
significant IL-4 responses to STAPPAHGV and tetanus toxoid (p < 0.001). No IL-4 response was
detected in AntpMAPMUC1tet group compared to PBS (Figure 6B).
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Figure 6. In vivo IFN-γ and IL4 response to AntpMAPMUC1tet and AntpMAPMUC1tet + CpG
in HLA-A2 transgenic mice. HLA-A2 mice were injected i.d. on day 0, 10 and 17 with PBS,
100 µg AntpMAPMUC1tet and AntpMAPMUC1tet + CpG. Number of IFN-γ secreting cells (A)
and IL4-secreting cells (B) to MUC1A2 (STAPPAHGV) and tetCD4 recall antigens were analysed by
ELISpot assay. ConA (1 µg/mL) was used as an internal positive control (not shown). Results are
shown as mean spot-forming units (SFU)/5 × 105 cells ± SEM. Results are representative of three
separate experiments. * p < 0.05, ** p < 0.001.
2.7. o bination of p ith ntp 1tet Induces Enhanced In ivo ntigen Specific Cytotoxic Killing
The capacity of both 57BL/6 and L - 2 transgenic ice to generate antigen specific killing
in vivo follo ing i unisation as assessed using in vivo CTL assays [24,44]. To detect MUC1Kb
restricted lysis, groups of 6 C57BL/6 mice were injected with PBS, 100 ug AntpMUC1tet with or ithout
CpG. Splenocytes from naïve mice were prepared, pulsed with SAPDTRPAP peptide and labelled with
carboxyfluorescein diacetate succinimidyl ester (CFSE) at high or low concentrations and subsequently
adoptively transferred into immunised mice. Mice pre-immunised with AntpMAPMUC1tet + CpG
generated significantly greater lysis (55 ± 3% vs. 80 ± %, p < 0.05) than mice immunised with
AntpMAPMC1tet alone (Figure 7A,B).
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Likewise HLA-A2 transgenic ice i nise ith AntpMAPMUC1tet + CpG showed
significantly greater MUC1A2 STAPPAHGV in vivo lysis (47 6% vs. 77 ± 3%, p < 0.05) than
mice immunised with AntpMAPMUC1 (Figure 7A,B). Therefore, in C57BL/6 and HLA-A2 transgenic
mice AntpMAPMUC1tet induces MUC1-specific T cells that secrete IFNγ when stimulated with H2-Kb
and HLA-A2-restricted CTL epitopes (above) and furthermore the induced T cells are cytolytic in vivo.
2.8. AntpMAPMUC1tet + CpG Immunisation Delayed Tumour Growth in Prophylactic Tumour Challenge
To evaluate the efficacy of AntMAPMUC1tet in tumour protection, groups of C57BL/6 mice (n = 8)
were immunised with PBS, 100 µg AntpMAPMUC1tet or 100 µg AntpMAPMUC1tet + 50 µg CpG on
days 0, 10 and 17. Seven days, after the last immunisation, mice were challenged subcutaneously with
2 × 105 B16-MUC1 cells on the abdomen [44,49]. Immunisation of mice with AntpMAPMUC1tet did
not retard B16-MUC1 tumour growth. In contrast, mice immunised with AntpMAPMUC1tet + CpG
exhibited significantly delayed tumour growth (Figure 8).
On day 3 , 2 out of 8 mice in AntpMAPMUC1tet + CpG immunised group were tumour free,
whilst all control PBS injected mice and 5 of 8 AntpMAPMUC1tet immunised mice succumbed to
tumour and had to be culled. The mean tumour size on day 28 in AntpMAPMUC1tet + CpG group was
significantly smaller (p < 0.05) at 28.6 ± 9.1 mm2, whilst tumour size in control and AntpMAPMUC1
alone group was 61.5 ± 4.5 and 66.0 ± 6.1 mm2 respectively. In addition, mice immunised with
AntpMAPMUC1tet survived significantly longer (38.5 days) (p = 0.006) than controls (29.5 days) and
AntpMAPMUC1tet (32 days) immunised mice (Figure 8B).
Molecules 2018, 23, 2233 9 of 21Molecules 2018, 2 , x 9 of 21 
  
(A) (B) 
Figure 8. Tumour growth is delayed by immunization (A). C57BL/6 mice were immunised on days 0, 
10 and 17 with PBS (●), 100 µg AntpMAPMUC1tet (■) or 100 µg AntpMAPMUC1tet + 50 µg CpG (▲) 
then inoculated subcutaneously 7 days after final immunisation with 2 × 105 B16-MUC1 melanoma 
cells into the abdomen. Tumour growth was recorded. Data showing the product of individual 
perpendicular measurements (mm2) and days post tumour inoculation. Number of tumour-free mice 
(†) and number of surviving mice (★) is also shown. Kaplan–Meier survival curves for each 
immunised group are shown (B). 
On day 31, 2 out of 8 mice in AntpMAPMUC1tet + CpG immunised group were tumour free, 
whilst all control PBS injected mice and 5 of 8 AntpMAPMUC1tet immunised mice succumbed to 
tumour and had to be culled. The mean tumour size on day 28 in AntpMAPMUC1tet + CpG group 
was significantly smaller (p < 0.05) at 28.6 ± 9.1 mm2, whilst tumour size in control and 
AntpMAPMUC1 alone group was 61.5 ± 4.5 and 66.0 ± 6.1 mm2 respectively. In addition, mice 
immunised with AntpMAPMUC1tet survived significantly longer (38.5 days) (p = 0.006) than 
controls (29.5 days) and AntpMAPMUC1tet (32 days) immunised mice (Figure 8B). 
2.9. Induction of Long Term Immunity is Enhanced by CpG 
The induction of long term antigen specific T cell responses in vivo following immunisation 
C57BL/6 mice was assessed by ELISpot and in vivo CTL assays performed 40 days after the last 
immunization. Mice were injected on days 0, 10, and 17 and i.d. with PBS, 100 µg AntpMAPMUC1tet 
or 100 µg AntpMAPMUC1tet with 50 µg CpG and T cell responses, measured 40 days after final 
immunisation. 
Mice immunised with AntpMAPMUC1tet alone revealed IFN-γ responses against SAPDTRPAP 
and tetCD4 compared to control mice. Immunisation with AntpMAPMUC1tet + CpG induced 
significantly higher levels of IFN-γ responses against SAPDTRPAP (MUC1Kb) and tetCD4 compared 
to AntpMUC1tet mice (p < 0.05) (Figure 9A). AntpMAPMUC1tet and AntpMAPMUC1tet + CpG 
induced significant IL-4 responses to SAPDTRPAP and tetCD4 (Figure 9B). It was also apparent that 
the addition of CpG enhanced IFNresponses to MUC1Kb and tetCD4 and IL4 responses to MUC1Kb. 
 
Figure 8. Tumour growth is delayed by immunization (A). C57BL/6 mice were immunised on days 0,
10 and 17 with PBS ( ), 100 µg AntpMAP UC1tet () or 100 µg Antp APMUC1tet + 50 µg CpG (N)
then inoculated subcutaneously 7 days after fi unisation with 2 × 105 B16-MUC1 elanoma
cells into the abdomen. Tumour growth orded. Data showing the product of individual
perpendicular measurements (m 2) and days post tumour inoculation. Number of tumour-free mice
(†) and number of surviving mice (F) is also shown. Kaplan–Meier survival curves for each immunised
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2.9. Induction of Long Term Immunity is Enhanced by CpG
The induction of long term antigen specific T cell responses in vivo following immunisation
C57BL/6 mice was assessed by ELISpot and in vivo CTL assays performed 40 days after the last
immunization. Mice were injected on days 0, 10, and 17 and i.d. with PBS, 100 µg AntpMAPMUC1tet
or 100 µg AntpMAPMUC1tet with 50 µg CpG and T cell responses, measured 40 days after
final immunisation.
Mice immunised with AntpMAPMUC1tet alone revealed IFN-γ responses against SAPDTRPAP
and tetCD4 compared to control mice. Immunisation with A tpMAPMUC1tet + CpG induced
significantly higher levels of IFN-γ responses against SAPDTRPAP (MUC1Kb) and tetCD4 compared
to AntpMUC1tet mice (p < 0.05) (Figure 9A). AntpMAPMUC1tet and AntpMAPMUC1tet + CpG
induced significant IL-4 responses to SAPDTRPAP and tetCD4 (Figure 9B). It was also apparent that
the addition of CpG enhanced IFNγresponses to MUC1Kb and tetCD4 and IL4 responses to MUC1Kb.
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Figure 9. Long term in vivo IFN-γ and IL-4 respons tp APMUC1 et and AntpMAPMUC1tet
+ CpG. C57BL/6 mice were inject on day 0, 10 and 17 with PBS, 100 µg AntpMAPMUC1tet
and t P UC1tet + CpG. Number of IFN-γ secreting cells (A) and IL4-secreting cells (B) to
MUC1Kb (SAPDTRPAP) and tetCD4 antigens were analysed by ELISpot assay. ConA (1 µg/mL)
was used as an internal positive control (not shown). Results are shown as mean spot-forming units
(SFU)/5 × 105 cells ± SEM. Results are representative of three separate experiments. * p < 0.05.
Molecules 2018, 23, 2233 10 of 21
To detect long termMUC1Kb restricted lysis C57BL/6 mice were injected with CFSE labelled
cells pulsed with SAPDTRPAP peptide as described previously. Mice pre-immunised with
AntpMAPMUC1tet + CpG generated significantly greater (p < 0.001) MUC1Kb-specific lysis than mice
immunised with AntpMAPMUC1tet peptide alone, 41 ± 2 vs. 65 ± 2% (Figure 10A,B).
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Figure 10. Long term cellular immune responses in Antp AP t i
as in vivo CTL killing ass ys. (A) C57BL/6 mice were immunised i.d. ith PBS, 100
AntpMAPMUC1te or 10 µg AntpMAPMUC1tet + 50 µg CpG and t t ifi l i
was det rmined eight days after im unisation calculated as: {[1 − (ratio CFSElow/ h f
mice/ratio CFSElo CFSEhigh of i munised mice)] × 100}. R presentative histograms are shown.
(B) D ta is pr sented as mean % of killing ± SEM (n = 6). ** p <0 .001.
2.10. Generation of MUC1-Specific Antibodies
At the time of ELISpot assay sera was also collected from C57BL/6 mice to determine antibody
responses 2 weeks and 40 days after the last immunisation. The levels of IgG subclasses were analysed,
as they provide an indication of the Th1 versus Th2 nature of the immune response. Mice immunised
with AntpMAPMUC1tet generated predominantly IgG1 responses significantly greater (p < 0.001)
than that of PBS injected mice 2 weeks post immunisation (Figure 11A). Mice immunised with
AntpMAPMUC1tet + CpG generated significantly greater total IgG antibody titres (p < 0.05) than
AntpMAPMUC1tet alone and were predominantly of the IgG2a subclass.
To ascertain longer term antibody responses immunised mice were bled 40 days after
last immunisation and sera analysed for total IgG, IgG1 and IgG2a isotypes. The levels of
anti-MUC1-specific antibody was reduced in the AntpMAPMUC1tet immunised group however,
AntpMAPMUC1tet with CpG sustained higher levels of anti-MUC1 antibody and were predominantly
of the IgG2a subclass (Figure 11B).
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stimulation. For presentation by MHC class I exogeneous antigens must enter the cytoplasmic 
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Figure 11. Short and long term MUC1-specific total IgG, IgG1 and IgG2a subclass antibody responses.
C57BL/6 mice were injected on day 0, 10 and 17 i.d. with PBS, 100 µg AntpMAPMUC1tet or 100 µg
AntpMAPMUC1tet + 50 µg CpG and 14 days after last immunisation mice (short term) (A) or 40 days
after the last immunisation (long term) (B) were bled and total IgG, IgG1 and IgG2a antibody responses
to Cp13-32 (MUC1 VNTR) were determined via ELISA. Data presented as mean titre ± SEM (n = 4).
Statistical difference compared to naïve mice: * p < 0.05; ** p < 0.001.
3. Discussion
Various therapeutic approaches are being developed and investigated to imp ve the treatment
for cancer patients. A prophylactic or therapeutic vaccine for cancer would e of great ben fit.
Delivery of target antigen into professional antigen presenting cells (APC) is the first step for inducing
antigen-specific T cell responses. Exogenous antigens taken up by endocytosis are transferred
to the lysosomal compartment, processed and presented by MHC class II for T cell stimulation.
For presentation by MHC class I exogeneous antigens must e ter the cytoplasmic compartment for
processing by the proteasome for loading class I molecul s in the endoplasmic reticulum. Various
strategies have been used to delivery antigens into professio al antigen presenting cells [3,50–54].
I addition to cytoplasmic delivery to dendritic cells successful priming of T cells is dependent upon
wo signals one from interaction of peptide loaded MHC class I mol cule with the T cell receptor and
the other from co-stimul ory molecules CD80 and CD86 binding to CD28 on T cells.
Co-vaccination with adjuvants is widely investigated as a means t further en ance the im une
sponse [55]. TLR are a family of cons rved pattern recognition receptors f und on everal cell types,
including DCs, that recognise specific molecul r patterns present i pathogen su h as bacteria, virus
or fungi [56,57]. The activation of TLR by their corresponding ligands n DCs results in the induction
of a mature ph notype of DCs, inducing the up-regulation of MHC and co-stimulatory (CD80 and
CD86) molecules and the production of inflammatory cytokines (IL-12, type I IFN) for optimal T cell
priming, thus potentially augmenting T cell stimulatory capacity [47]. Linear synthetic penetratin or
Tat CPP containing peptide or protein immunogens internalise into DC, engender potent immune
responses and anti-tumour effects. Mechanistic studies, utilising biochemical inhibitors, have shown
that these immunogens are taken up by a combination of direct translocation into the cytoplasm or via
an energy dependent endocytic mechanism. The CPP-mediated endocytosed antigens are processed
and presented by MHC class II, as well as MHC class I via cross-presentation pathway [4,29,43].
Interestingly, penetratin or Tat-based immunogens do not mature or activate DC or induce cytokine
production but capable of inducing therapeutic cytotoxic T cell responses without any adjuvants.
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However, several studies have shown increased anti-tumour activity when CPP-based immunogens
are co-immunised with a TLR agonist [24,42].
Thus far CPP based immunogens have included only linear synthetic peptides, recombinant
fusion proteins or covalent conjugates. For this study we designed a novel branched tripartite synthetic
peptide incorporating penetratin to facilitate cytoplasmic delivery, a tetanus toxoid universal cell
epitope for CD4 help which should enhance long term immune responses and a single repeat from the
MUC1 tumour associated antigen which incorporates several Tc epitopes (Figure 1A).
Penetratin or Tat containing immunogens do not mature DC in vitro or in vivo and similarly
AntpMAPMUC1tet fails to activate DC (Figure 4). Here we also demonstrate that like other Tat or
penetratin-based CPP the tripartite CPP can internalise antigenic peptides into DC (Figure 2C) [29,43,44].
In contrast to the tripartite peptide, alone co-administration of the tripartite peptide with CpG
stimulates maturation of DC in vivo, which is evident by elevated expression of the co stimulatory
molecules CD40, CD80, CD86 and MHC II (Figure 4). Previously, it has been shown that immunogens
incorporating Antp is rapidly uptaken by DC in an ATP dependent manner, and processed by
a proteasome and TAP independent pathway for presentation and loading onto MHC class I
molecules [29,43]. Here we show that in vivo AntpMAPMUC1tet selectively accumulate in DC
in the lymph node following i.d. immunisation (Figure 3). Therefore, given DC proficiency in
cross presentation, it is possible that the efficiency by which Antp incorporating peptides are
presented by MHC class I may be due, in part, to their high specificity for DC. Furthermore, mice
vaccinated with AntpMAPMUC1tet + CpG show enhanced antigen specific IFN-γ and IL-4 T cell
responses compared with AntpMAPMUC1tet vaccination alone and induced delayed tumour growth.
Vaccination generated long term antibody and promoted a Th1 response, characterised by a higher
ratio of IgG2a antibody/IgG1 antibodies (Figure 11B). Previously topical application of a synthetic
peptide of penetratin fused to the OVA CTL epitope SIINFEKL, or penetratin chemically conjugated to
a 4-armed multiple antigen peptide containing co administered with CpG was shown to confer tumour
protection against E.G7-OVA tumour cells [32]. Similarly, mice vaccinated with TAT-CEA + CpG
showed enhanced CTL activity and induced a higher ratio of IgG2a/IgG1 CEA specific antibodies
compared with CEA alone, CEA + CpG or TAT-CEA immunisation [58] and significantly higher
survival rates in a tumour model using MC38/CEA2 [58]. Results presented here with the novel
branched tripartite peptide concur with those of Woo et al. (2008) where AntpMAPMUC1tet + CpG
immunisation was shown to induce both a potent cellular and humoral immune response. Mice
immunised with AntpMAPMUC1tet + CpG generated significantly higher cellular and humoral
responses against MUC1 epitopes compared to both AntpMAPMUC1tet and PBS groups in C57BL/6
mice (Figures 5, 6 and 11). Moreover, only mice immunised with AntpMAPMUC1tet + CpG showed
delayed tumour growth when challenged with the melanoma B16 MUC1 expressing tumour cell line
(Figure 8). Mice immunised with AntpMAPMUC1tet alone did not confer an anti-tumour response.
Although CTLs are recognized as the effector T cells in an anti-tumour response, CD4+ Th cells
have a significant role in immunity against tumours, necessary for the activation of antigen specific
effector cells and recruitment of cells of the innate immune system [59,60]. Both AntpMAPMUC1tet
and AntpMAPMUC1tet + CpG immunisation generated significantly higher IL-4 responses against
tetanus toxoid when compared to control group.
A Th response can be defined as Th1 or Th2, depending on phenotype and cytokine
production [60]. The ability of TLR activated APC to activate CD4+ T cells and shape a Th1
immune response has been well described [61]. Mice immunised with AntpMAPMUC1tet + CpG
generated significantly greater total IgG antibody titres than AntpMAPMUC1tet. Moreover,
AntpMAPMUC1tet + CpG immunisation promoted significant levels of both IgG1 and IgG2a isotypes
compared to naïve mice (Figure 11B). Together with the capacity to generate an IL-4 response to
tetCD4 as detected by ELIspot assay, it is clear AntpMAPMUC1tet + CpG generates both a Th1 and
Th2 response.
Molecules 2018, 23, 2233 13 of 21
The generation of long lasting memory CD8+ T cells in vivo is essential for a host to defend against
a tumour. Evidence has suggested that the quantity, and prolonged existence of memory CD8+ T cells,
is determined by the type and strength of signals that T cells received [62]. In this study the ability
of co vaccination with CpG to induce long lasting cellular immunity was also compared. Analysis
of long term MUC1 specific in vivo lysis revealed that AntpMAPMUC1tet + CpG immunisation
promoted greater antigen specific killing than AntpMAPMUC1tet immunisation alone (Figure 10A,B).
Moreover, mice immunised withAntpMAPMUC1tet + CpG generated long term IgG and IgG2a
responses (Figure 11B). Overall this data suggests that the addition of CpG promoted long lasting
memory T cells in vivo. Given AntpMAPMUC1tet alone does not promote augmented costimulatory
molecule expression, the enhanced co stimulation provided by DC may in part explain the more robust
T cell response and delayed tumour growth conferred when the vaccine is administered with CpG.
Such an adjuvant associated property is clearly desirable for boosting immune responses. CpG has
been used as a vaccine adjuvant in many clinical trials and considered reasonably safe [63]. However,
several trials have noted increased frequency of mild-moderate dose-related local adverse effects such
as flu-like symptoms and it use may require close monitoring of patients.
In conclusion Antp can be used to deliver tripartite branched synthetic peptides incorporating
multiple CD8 and CD4 T cell epitopes. Moreover, co-immunisation with the adjuvant CpG promotes
enhanced antigen specific IFN-γ and IL-4 T cell responses, induces a Th1 response, characterised by a
higher ratio of IgG2a /IgG1 antibodies and delays tumour growth in vivo. Furthermore, vaccination
generated a long term CD8+ memory response. The validation of this form of antigen delivery
enables the ready design of other novel tailor made self adjuvanting immunogens, containing Antp
and Th epitope, with an appropriate polyepitope peptide of single or multiple TAA specificity for
immunotherapy for various cancers.
4. Materials and Methods
4.1. Peptides
Linear peptides were synthesized by Genescript Corporation (San Francisco, CA, USA). The purity
of peptides was determined by mass spectrometry and high performance liquid chromatography and
were >95% pure. Antp (penetratin) is a 16 amino acid (RQIKIWFQNRRMKWKK) Antennapedia
peptide. MUC1Kb (SAPDTRPAP) and MUC1A2 (STAPPAHGV) are H-2Kb and HLA-A2 CTL
epitope peptides, respectively from the MUC1 VNTR region. C-PAHGVTSAPDTRPAPPGSTAP
(Cp13-32) is peptide from the MUC1 VNTR repeat containing the MUC1 H-2Kb epitope.
Tetanus toxoid peptide (tetCD4) (QYIKANSKFIGITEL) is a universal CD4 T helper epitope and
RQIKIWFQNRRMKWKKQYIKANSKFIGITEL (Antptet) is a fusion of Antp with tetCD4. The
branched tripartite peptide AntpMAPMUC1tet (Figure 1A), with PGSTAPPAHGVTSAPDTRPAPGS,
RQIKIWFQNRRMKWKKENK and QYIKANSKFIGITEL(C-terminus) was synthesised by Quality
Controlled Biochemicals (QCB, Hopkinton, MA, USA), and was >85% pure.
4.2. Conjugation of AntpMAPMUC1tet to Fluorochromes
To prepare Fluorescein-labelled conjugates, AntpMAPMUC1tet was dissolved in 0.2 M sodium
bicarbonate and fluorescein isothiocyanate (FITC), (Sigma-Aldrich, St. Louis, MO, USA) dissolved
in DMSO was added at a 2.5 fold molar excess. The solution was reacted for 16 h at RT and dialysed
overnight (O/N) in PBS at 4 ◦C to remove unreacted FITC. To prepare Alexa-488-labelled conjugates
for confocal microscopy experiments, AntpMAPMUC1tet was dissolved in 0.2 M sodium bicarbonate
buffer and labelled with a 2.5 molar excess of the N-hydroxysuccinimide ester of Alexa Fluro 488 dye
dissolved in DMSO (Molecular Probes, Eugene, OR, USA). To separate peptide from unreacted Alexa
Fluro dye reagent the solution was passed through a PD-10 column.
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4.3. Mice and Immunisations
C57BL/6 mice, aged 6–10 weeks were purchased from the animal facilities of the Walter and Eliza
Hall Institute (Parkville, Australia). HLA-A*0201/Kb transgenic mice (HLA-A2) were bred in the
facilities of the Burnet Institute (Victoria, Australia). All mice were maintained in the animal house
facilities of the Burnet Institute (Victoria, Australia) or RMIT University (Victoria, Australia). HLA-A2
transgenic mice express a chimeric class I molecule that consists of α1 and α2 domains of HLA-A2.1
and the α3 transmembrane and cytoplasmic domains of H-2Kb [64].
For immunisation experiments mice were injected three times on days 0, 10 and 17 intradermally
(i.d.) at the base of tail. Mice were injected with 100 µg AntpMAPMUC1tet. All animal experiments were
approved by the Austin Health and RMIT animal ethics committees (Approval No: E/0842/2009/F).
4.4. Adjuvants
CpG-ODN 1668 (5′-TCC ATG ACG TTC CTG ATG CT-3′) with phosphorothioate linkages was
synthesized by Geneworks (Adelaide, Australia) and dissolved in sterile PBS and stored at −20 ◦C.
For immunisation experiments peptides were mixed with CpG (50 µg) and co administered with
the peptide into mice three times on days 0, 10 and 17 i.d. at the base of tail.
4.5. ELISA
Peptides were coated on a polyvinyl chloride (PVC) microtiter plate at 10 µg/mL in buffer (0.2 M
NaHCO3 buffer, pH 9.6) overnight at 4 ◦C and non-specific binding was blocked with 2% bovine serum
albumin (BSA) for 1 h at RT. After washing (0.05% Tween 20/phosphate buffered saline (PBS)), serial
dilutions of the anti-MUC1 antibody, BC2 recognizing SAPDTRPAP (MUC1Kb) or 1.3.14 recognizing
STAPPAHGV (MUC1A2) were added and incubated for a further 1 h at RT. Plates were then washed
and bound antibody was detected using HRP-conjugated sheep anti-mouse antibody (Amersham, UK).
Responses were detected with TMB substrate solution (Invitrogen, Carlsbad, CA, USA) and stopped
with 1M HCl. Absorbance was read at 450 nm.
4.6. Generation of Bone Marrow Derived Dendritic Cells (BMDC)
Bone marrow cells from C57BL/6 female mice were collected by flushing the tibias of hind legs
and treated with ACK lysis buffer (0.15 M NH4Cl, 1 mM KHCO3 and 0.1 mM Na2EDTA) to lyse
erythrocytes. Cells were washed and cultured at 5 × 105 cells/ml in 24 well plates with complete
RPMI-1640 medium (10% (v/v) heat inactivated fetal calf serum, 4 mM L-glutamine, 100 U/mL
penicillin, 100 µg/mL streptomycin sulphate and 100 µM β-mercaptoethanol) with 10 ng/mL of
recombinant mouse granulocyte macrophage colony-stimulating factor (GM-CSF) and IL-4 (BD
Pharmingen, San Diego, CA, USA). At day 6 cells were >80% CD11c+.
4.7. Internalisation into BMDC
Day 6 cultured C57BL/6 BMDC were pulsed at 5, 20, 100 and 200 µg/mL with peptides for a
1 h at 37 ◦C in serum free media. Due to cell fixation causing artefactual uptake of CPP peptides
all uptake experiments were performed by measuring the surface and intracellular presence, with
results expressed as intracellular percentage—surface percentage [23,44]. For surface staining (detect
extracellular peptide) DC were washed with 0.5% BSA/PBS and incubated with the anti-MUC1
monoclonal antibody BC2 (diluted in 0.5% BSA/PBS) for 30 min at 4 ◦C. Cells were washed and
anti-(Fab’)2-FITC (Chemicon, Melbourne, Australia) was added in 0.5% BSA /PBS for a further 30 min
at 4 ◦C. For intracellular staining (detect extracellular and intracellular peptide) cells were fixed with
2% paraformaldehyde for 10 min at room temperature and washed and permeabilised with 0.25%
saponin/PBS for 10 min. Cells were then stained as above in 0.25% saponin/PBS. Kinetics of uptake
was also assessed by adding peptides for various times (5–360 min) at a fixed concentration at 37 ◦C.
DC were resuspended in PBS and analysed by flow cytometry (BDCanto, BD Biosciences, San Jose, CA,
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USA). Results are expressed as intracellular percentage—surface percentage. Isotype controls were
used as negative control (background) staining.
4.8. In Vitro Maturation
Stimulants were added to day 4 GM-CSF grown BMDC culture. After 18 h incubation cells were
harvested washed and stained with anti-CD40, anti-CD80 and anti-CD86 conjugated to FITC, together
with the DC marker anti-CD11c (BD Pharmingen) for 20 min at 4 ◦C in 2% FCS/PBS. Cells were
washed and analysed via flow cytometry. Live BMDC population was gated based on the PI negative
cells and CD11c+ [65].
4.9. In Vivo Maturation
C57BL/6 mice were injected i.d. in the footpad with peptides. LPS (1 µg/mL) and PBS were used
as positive and negative controls respectively. 18 h later popliteal lymph nodes were isolated and
pooled (n = 4) and stained with CD11c-APC and maturation markers (CD40, CD80, CD86, and MHC
class II) assessed by flow cytometry. Live cells were gated on PI staining and cells gated on CD11c+hi
staining [48].
4.10. In Vivo Binding Specificity
C57BL/6 mice were injected i.d. with 100 µg FITC-labelled AntpMAPMUC1tetFITC or PBS
in footpads for 18 h. Popliteal lymph nodes cells were isolated and pooled from mice (n = 3) and
cells labelled with fluorochrome-conjugated anti-CD3, anti-CD19, anti-CD11c and anti-F4/80 (BD
Pharmingen) to separate T cells, B cells, CD11chi DC and F4/80hi macrophages respectively [45,48].
To assess binding of DC subsets popliteal lymph nodes were pooled (n = 4) and resuspended in
free balanced salt solution (BSS) with 0.1 M EDTA (pH 7.2) to dissociate T cells from DCs and incubated
with CD11c microbeads (10 µL beads/107 cells) (Miltenyi Biotec, Bergisch Gladbach, Germany) for 30
min at 4 ◦C. Cells were washed and resuspended in BSS and passed through AutoMACS columns
(Miltenyi Biotech, Germany). Purity of cells (CD11c+) was >90%.
To differentiate DC subpopulations, cells were stained with biotin-labelled anti-DEC205 and
streptavidinPE-Cy7 and anti-CD8-PE together with anti-CD11cAPC and analysed for FITC expression.
Three major subsets in the popliteal lymph nodes subsets were identified: CD8– DEC205– (immature),
CD8+ DEC205– (immature) and CD8low DEC205+ DCs (migratory) [46].
4.11. Enzyme-Linked Immunosorbent Spot-Forming Cell Assay (ELISpot)
To determine effector immune response splenocytes from immunised C57BL/6 and HLA-A2
transgenic mice immunised i.d. on days 0, 10 and 17 were isolated 14 days after final immunisation
and assessed by ELISpot for IFN-γ and IL-4 secretion. To determine long term immune responses
splenocytes from C57BL/6 mice were isolated 40 days after final immunisation. MultiScreen filter
plates (Millipore, Billerica, MA) were coated with 70 µL 5 µg/mL anti-mouse IFN-γ antibody (AN18)
or anti-mouse IL-4 antibody (Mabtech, Stockholm, Sweden) overnight at 4 ◦C. Plates were washed
six times with sterile PBS and blocked with 200 µL complete RPMI media for 2 h at 37 ◦C. Spleen
cells (5 × 105/well) in 100 µl of complete medium were incubated with 20 µg/mL various recall
antigens for 18 h in IFN-γ ELISpot and 24 h in IL-4 ELISpot. Recall antigens included SAPDTRPAP,
STAPPHAGV and tetCD4. Concanavalin A (ConA) (1 µg/mL) or cells alone were used as positive and
negative controls respectively. Triplicate wells were set up for each condition. Cells were discarded after
washing (PBS) and 1 µg/mL biotinylated anti-mouse IFN-γ antibody or biotinylated anti-IL-4 antibody
(Mabtech) was added for 2 h at RT. The plates were washed with PBS and 1ug/mL streptavidin-alkaline
phosphatase (AP) (Mabtech) added at room temperature for 2 h. Spots of activity detected using
a colorimetric AP-conjugate substrate kit (Bio-Rad Laboratories, Foster City, CA, USA). Cytokine
spots were counted with an AID ELISpot Reader system (Autoimmun Diagnostika GmbH, Strassberg,
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Germany). Data are presented as mean spot-forming units (SFU) per 5 × 105 cells ± standard error of
the mean (SEM).
4.12. Antibody ELISA
Sera was collected from C57BL/6 and HLA-A2 transgenic mice 14 or 40 days after final
immunisation via orbital bleed. Red blood cells pelleted by centrifugation at 13,000 rpm for 10 min
and serum was aspirated and stored at −20 ◦C until use.
The MUC1 VNTR peptide Cp13-32 (C-PAHGVTSAPDTRPAPGSTAP) was coated onto PVC
microtiter plates at 10 µg/mL in 0.2M NaHCO3 buffer, pH 9.6, overnight at 4 ◦C. After washing
(0.05%Tween 20/PBS), non-specific binding was blocked with 2% BSA/PBS for 1 h at RT. Serial
dilutions of sera were added (in 2% BSA/PBS) and incubated for a further 2 h at RT. Plates were
washed and bound antibody detected using horseradish peroxidase-conjugated sheep anti-mouse IgG
(Amersham, UK). To determine Ig subclasses plates were washed and bound antibody detected using
biotin conjugated sheep anti-mouse IgG1 or IgG2a (BD Pharmingen). Plates were washed as described
above and streptavidin HRP added for 1 h at RT. Responses were detected with TMB substrate solution
and stopped with 1M HCl. Absorbance was read at 450 nm. End-titre was defined as the last value in
the titration to remain above the corresponding control value, where the control was calculated as the
mean OD values + 2 SD of naive mouse serum samples (4 mice) at each titration point.
4.13. Confocal Microscopy
Day 5 BM-CSF and IL-4 grown BMDC (5 × 104 cells) were seeded in eight well chambered cover
glasses (Nunc) O/N at 37 ◦C. The next day culture media was aspirated and replaced with 200 µL
Hank’s Buffered Salt Solution (HBSS) and pulsed with Alexa-labelled AntpMAPMUC1tet peptide for
2 h 37 ◦C. Hoechst nuclear stain (10 µg/mL) (Molecular Probes) was added in for 15 min at 37 ◦C. Cells
were washed extensively and visualized using laser scanning microscope [43]. To prevent fixation
artefacts all measurements of peptide uptake were performed with living, non-fixed cells. For inhibition
of internalisation BMDC were pre incubated with and without cytochalasin D (Sigma, Gillingham,
UK) at 10 µg/mL which blocks phagocytosis for 45 min at 37 ◦C prior to pulsing with AntpMUC1tet.
4.14. Generation of Human Monocyte Derived Dendritic Cells (MoDC)
In order to generate MoDC, peripheral blood mononuclear cells (PBMCs) were isolated from the
buffy coat of healthy individuals (Australian Red Cross) [66]. Use of de-identified buffy coats from the
Australian Red Cross was approved by the Alfred Health Research Ethics Committee (Approval No:
162/09). Buffy coats were diluted 1:1 in sterile PBS and PBMC isolated by Ficoll-Paque density gradient
centrifugation (GE Healthcare Bio-sciences, Uppsala, Sweden). Isolated PBMCs were resuspended
at 107 cells/20 uL of anti-CD14 microbeads (Miltenyi, Germany) in EDTA-PBS/0.5%BSA buffer and
incubated at 4 ◦C for 20 min. Cells were washed and passed through the Automacs cell-sorting
system and CD14+ monocytes collected by positive selection (AutoMACS). CD14+ cells cultured with
20 ng/mL recombinant human GM-CSF and 10 ng/mL IL-4 for 6 days (BD Pharmingen). Purity
of MoDC was confirmed by staining with anti HLA-DRPerCP and Lin–veFITC cocktail (CD3, CD14,
CD16, CD19, CD20, CD56) (BD Pharmingen).
4.15. Generation of Tetanus Toxoid-Specific T Cell Lines
PBMC were separated from buffy coats via density gradient centrifugation using Ficoll-Paque
PLUS (GE Healthcare). PBMC were resuspended at 5× 106/mL in complete AB media (RPMI1640, 10%
AB serum, Pen/Strep, HEPES, L-GLUT, NEAA, Sodium Pyruvate (Invitrogen), 2-mercaptoethanol)
was stimulated with 20 µg/mL of tetCD4 and 5 µg/mL CpG in a 24 well plate. Three days later,
another 1ml complete AB media supplemented with 25U/mL IL-2 (R & D Systems), 10 ng/mL IL-15
and 10 ng/mL IL-7 (Peprotech) was added. Seven-10 days after initial priming, cells were re-stimulated
with autologous MoDC pulsed with 20 µg/mL tetCD4 peptide. On the following day, 1ml supernatant
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was exchanged for fresh complete AB media containing 25 U/mL IL-2. This was repeated every 3–4
days. tetCD4-specific T cell lines were generated by FACS sorting. IFNγ secreting cells specific for
tetCD4 peptides were sorted using the FACS Aria following a 4 h incubation with tetCD4-pulsed
MoDC. IFNγ secreting cells were identified using the IFNγ secretion and detection assay (Miltenyi
Biotech) performed according to manufacturer’s protocol.
4.16. Analysis of Antigen-Specific T Cell Responses
MoDC (2 × 105/well) were prepared by pulsing with an irrelevant peptide or tetCD4 (20 µg/mL)
for 1hr in serum free media. Pulsed MoDC were added at about a 1:5 ratio (4 × 104/well) in 100 µL to
the duplicate T cell wells and incubate for 1hr at 37 ◦C 5% CO2. 50 µL media containing Golgi-Stop
(0.1 µL per 200 uL T cell/MoDC co-culture) was added and cells were stained for surface markers CD8
and CD4, fixed and permeabilised, then stained for accumulation of intracellular IFNγ using CD4
APC-Cy7, CD8 FITC and IFNγ PE-Cy7(BD) with the Cytofix/CytoPerm Kit (BD). Antigen-specific
T cells were identified by flow cytometry comparing IFNγ+ CD4 and CD8 T cells in the presence of the
peptide of interest with the irrelevant peptide controls.
4.17. Prophylactic Tumour Protection
Groups of 8 C57BL/6 mice were injected intradermally (i.d.) at the base of tail with PBS, 100 µg
of AntpMAPMUC1tet or 100 µg AntpMAPMUC1tet with 50 µg CpG on days 0, 10 and 17. Seven
days following the last immunisation, mice were shaved on the abdominal area and challenged
subcutaneously (s.c.) with 2 × 105 MUC1-B16 melanoma cells suspended in 100 µL PBS. Expression
of MUC1 on MUC1-B16 cells was confirmed by flow cytometry prior to challenge. The growth of
tumours was monitored by measuring the two perpendicular diameters using callipers and the results
were expressed as their product.
4.18. Statistical Analysis
Mean values were compared using unpaired t-tests and one-way ANOVA using Graphpad
InStat version 3.0a (GraphPad Software, San Diego, CA, USA). Two p-value thresholds were used for
immunogenicity assays: * p < 0.05 to indicate a significant difference, ** p < 0.001 to indicate a highly
significant difference.
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